1 research outputs found
Natural-Based Indirubins Display Potent Cytotoxicity toward Wild-Type and T315I-Resistant Leukemia Cell Lines
Drug resistance in chronic myelogenous
leukemia (CML) requires
the development of new CML chemotherapeutic drugs. Indirubin, a well-known
mutikinase inhibitor, is the major active component of “Danggui
Longhui Wan”, a Chinese traditional medicine used for the treatment
of CML symptoms. An in-house collection of indirubin derivatives was
screened at 1 μM on wild-type and imatinib-resistant T315I mutant
CML cells. Herein are reported that only 15 analogues of the natural
6-bromoindirubin displayed potent cytotoxicity in the submicromolar
range. Kinase assays in vitro show that eight out of the 15 active
molecules strongly inhibited both <i>c</i>-Src and Abl oncogenic
kinases in the nanomolar range. Most importantly, these eight molecules
blocked the activity of T315I mutant Abl kinase at the submicromolar
level and with analogue <b>22</b> exhibiting inhibitory activity
at the low nanomolar range. Docking calculations suggested that active
indirubins might inhibit T315I Abl kinase through an unprecedented
binding to both active and Src-like inactive conformations. Analogue <b>22</b> is the first derivative of a natural product identified
as an inhibitor of wild-type and imatinib-resistant T315I mutant Abl
kinases